NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals. Moleac is dedicated in finding, developing, and commercializing new...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug...
